Evidence map›Paper›PMID 39367172›Full record

ArticleLeukemia2025

Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis-insights from a multicenter study.

Yu-Hung Wang, Chao-Hung Wei, Chien-Chin Lin, Carmelo Gurnari, Hussein Awada, Lina Benajiba, Rafael Daltro de Oliveira, Juliette Soret-Dulphy, Bruno Cassinat, Andrius Zucenka and 13 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Yu-Hung Wang *Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. yuhungwang922@gmail.com.ORCID 0000-0003-4483-5627
Chao-Hung Wei *Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chien-Chin LinDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0001-7160-2285
Carmelo GurnariDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Hussein AwadaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-1445-7947
Lina BenajibaCentre d'Investigations Cliniques, Hospital Saint Louis and University Paris Cité, Paris, France.
Rafael Daltro de OliveiraCentre d'Investigations Cliniques, Hospital Saint Louis and University Paris Cité, Paris, France.ORCID 0000-0002-9252-2046
Juliette Soret-DulphyCentre d'Investigations Cliniques, Hospital Saint Louis and University Paris Cité, Paris, France.
Bruno CassinatLaboratoire de Biologie Cellulaire, Hospital Saint Louis and University Paris Cité, Paris, France.ORCID 0000-0002-6514-3905
Andrius ZucenkaHematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Adrián Mosquera OrgueiraHematology Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.ORCID 0000-0003-4838-6750
Chang-Tsu YuanDepartment of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
Sze-Hwei LeeDivision of Cellular Therapy, Department of Integrated Diagnostics and Therapeutics, National Taiwan University Hospital, Taipei, Taiwan.
Chi-Yuan YaoDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0001-5052-9445
Kristian GurashiEpigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, UK.
Hsin-An HouDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Kiran BattaEpigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, UK.ORCID 0000-0002-3494-0979
Manuel Mateo Pérez EncinasHematology Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
Wen-Chien ChouDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0003-2967-698X
Jaroslaw P MaciejewskiDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-6837-4346
Daniel H WisemanEpigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, UK.ORCID 0000-0003-0715-1402
Jean-Jacques KiladjianCentre d'Investigations Cliniques, Hospital Saint Louis and University Paris Cité, Paris, France.ORCID 0000-0002-8121-438X
Hwei-Fang TienDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. hftien@ntu.edu.tw.ORCID 0000-0002-1384-5593

Funding

Ministry of Health and Welfare, Taiwan | Health Promotion Administration, Ministry of Health and Welfare (Health Promotion Administration of the Taiwan Ministry of Health and Welfare) MOHW 112-TDU-B-211-124001Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan) MOST 107-2314-B-002-013
6 · The paper itself

Abstract

In addition to high-molecular risk (HMR) mutations (ASXL1, EZH2, SRSF2, IDH, and U2AF1

Indexed as

Gene FrequencyJanus Kinase 2MutationPrimary MyelofibrosisAdultAgedAged, 80 and overFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedPrognosisSurvival RateJAK2 protein, humanJanus Kinase 2

Identifiers

PMID39367172

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.